“What you have to do in a market like that, where it’s highly genericized, is first you have to have a clinical differentiation,” says Richard Lowenthal, CEO of ARS Pharmaceuticals. “You have to have a benefit to the community, benefit to the patient population. Neffy achieves that very effectively by providing an option that’s very simple — it’s easy to carry, it’s very easy to use.” In this episode of Vanguards of Health Care, Richard sits down with Bloomberg Intelligence analyst Ann-Hunter van Kirk for an in-depth interview about how the company has navigated the commercial launch of its needle-free epinephrine nasal spray, neffy, in a highly competitive genericized market.

&ldquo;What you have to do in a market like that, where it&rsquo;s highly genericized, is first you have to have a clinical differentiation,&rdquo; says&nbsp;Richard Lowenthal, CEO of ARS Pharmaceuticals. &ldquo;You have to have a benefit to the community, benefit to the patient population. Neffy achieves that very effectively by providing an option that&rsquo;s very simple &mdash; it&rsquo;s easy to carry, it&rsquo;s very easy to use.&rdquo; In this episode of&nbsp;Vanguards of Health Care, Richard sits down with&nbsp;Bloomberg Intelligence&nbsp;analyst&nbsp;Ann-Hunter van Kirk&nbsp;for an in-depth interview about how the company has navigated the commercial launch of its needle-free epinephrine nasal spray, neffy, in a highly competitive genericized market.

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Health Care by Bloomberg Intelligence

ARS Pharma’s Clinical Differentiation

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/f057e55a-c161-40f6-82bb-b39400e6cda8/transcript